Eris Lifesciences · NSE: ERIS · BSE: 540596
Q3 FY23 results · Oct–Dec 2022
Eris Lifesciences reported revenue from operations of ₹423.26 crore and net profit of ₹100.23 crore for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 423.26 | — | — | 460.51 | −8.1% |
| Other income | 2.24 | — | — | 5.17 | −56.8% |
| Total income | 425.50 | — | — | 465.68 | −8.6% |
| Profit before tax | 106.54 | — | — | 120.93 | −11.9% |
| Net profit for the period | 100.23 | — | — | 119.38 | −16.0% |
| Attributable to shareholders of the company | 101.86 | — | — | 120.30 | −15.3% |
| EPS, basic (₹) | 7.49 | — | — | 8.84 | −15.3% |
| Net margin (%) | 23.7 | — | 25.9 |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 332.01 | 304.63 | +9.0% | 355.37 | −6.6% |
| Other income | 3.48 | 5.84 | −40.4% | 6.15 | −43.5% |
| Total income | 335.49 | 310.47 | +8.1% | 361.52 | −7.2% |
| Profit before tax | 110.23 | 114.32 | −3.6% | 123.81 | −11.0% |
| Net profit for the period | 99.38 | 104.06 | −4.5% | 115.20 | −13.7% |
| EPS, basic (₹) | 7.31 | 7.66 | −4.6% | 8.47 | −13.7% |
| Net margin (%) | 29.9 | 34.2 | 32.4 |
Consolidated
- Filed with BSE
- 18 Jan 2023, 16:12 IST
- Board meeting
- 17 Jan 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 Jan 2023, 16:12 IST
- Board meeting
- 17 Jan 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE